Drug intelligence / Profile preview

SentiKin

Development stage: Unknown
Lead developer: Elanco
Modality: Small Molecules
Administration: Oral

Overview

**SentiKin** (flupirtine) is a veterinary analgesic developed by Kindred Biosciences for the treatment of post-operative pain in dogs. It is a potassium channel opener that provides non-opioid, non-narcotic pain relief by modulating neuronal excitability without significant anti-inflammatory effects. The drug advanced to a pivotal clinical study in dogs, with pharmacokinetic studies also completed for an extended-release formulation in postoperative pain for cats. Development focused on companion animal health, particularly acute pain management following surgery.[16][17][21]

Brand names: SentiKin

Targets

Kir (Inward-rectifier potassium channels)

Beyond the preview

Go deeper on SentiKin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SentiKin.

Explore the full profile